On Friday, Shares of Vereit Inc (NYSE:VER), added 1.17% and closed at $10.37 in the last trading session. The last trading range of the stock ranges between $10.20 and $10.41. VEREIT, Inc. (VER) (“VEREIT” or the “Company”) declared that it anticipates to issue, jointly with its operating partnership, VEREIT Operating Partnership, L.P., its third quarter 2016 Quarterly Report on Form 10-Q on Wednesday, November 2, 2016.
The Company will also host an earnings conference call via audio webcast on that same day at 1 p.m. Eastern Time to discuss the financial results. The call will be conducted by Glenn J. Rufrano, VEREIT’s Chief Executive Officer, and Michael J. Bartolotta, VEREIT’s Chief Financial Officer.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), dropped -0.15% and closed at $13.69 in the last trading session. The last trading range of the stock ranges between $12.95 and $13.82. The company’s Market capitalization is $2.63 Billion with the total Outstanding Shares of 192.71 million. ARIAD Pharmaceuticals, Inc. (ARIA) recently declared that its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) has received approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for Iclusig® (ponatinib) for the treatment of chronic myeloid leukemia (CML) resistant or intolerant to preceding drug treatment and relapsed or treatment resistant Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
“Our partnershipwith Otsuka has resulted in recently’s approval of Iclusig in Japan, providing an important new treatment for patients with refractory CML and Ph+ ALL,” stated Paris Panayiotopoulos, president and chief executive officer of ARIAD. “Japan represents a large market opportunity for Iclusig and its first approval in Asia. We are committed to expanding patient access and to continuing our successful partnership with Otsuka as evidenced by recent marketing applications for Iclusig presented in Korea and Taiwan.”
This approval triggers a $10 million milestone payment to ARIAD from Otsuka under the parties’ partnershipagreement entered in December 2014.
”Treatment failure affects a substantial proportion of CML patients treated with tyrosine kinase inhibitors because of resistance or intolerance. For these patients living with CML in Japan, we are grateful to have Iclusig as a new approved treatment option,” said Arinobu Tojo, M.D., Ph.D, deputy director, Research Hospital, The Institute of Medical Science at the University of Tokyo.